Showing results (11-20 of 24) with videos related to
Sort By:
Pageof 3
Frontiers in Immunology|August 13, 2019
Tuning the Tumor Myeloid Microenvironment to Fight CancerNadine S Jahchan, Adriana M Mujal, Joshua L Pollack, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 29, 2013
Preclinical efficacy of the anti-hepatocyte growth factor antibody ficlatuzumab in a mouse brain orthotopic glioma model evaluated by bioluminescence, PET, and MRIErik S Mittra, Hua Fan-Minogue, Frank I Lin, et al.Proceedings of the National Academy of Sciences of the United States of America|June 13, 2002
Inhibition of glycolipid shedding rescues recognition of a CD1+ T cell lymphoma by natural killer T (NKT) cellsVenkataraman Sriram, Sungyoo Cho, Ping Li, et al.The Journal of Cell Biology|December 15, 2022
Hyperstabilization of T cell microvilli contacts by chimeric antigen receptorsCasey Beppler, John Eichorst, Kyle Marchuk, et al.Journal of Immunology (Baltimore, Md. : 1950)|May 23, 2002
Recycling CD1d1 molecules present endogenous antigens processed in an endocytic compartment to NKT cellsTonya J Roberts, Venkataraman Sriram, Philip M Spence, et al.Journal of Immunotoxicology|October 20, 2020
A T-cell-dependent antibody response study using a murine surrogate anti-PD-1 monoclonal antibody as an alternative to a non-human primate modelLisa M Plitnick, Beth Hutchins, Sheri Dubey, et al.Experimental Hematology|March 24, 2007
A role for natural killer T cells and CD1d molecules in counteracting suppression of hematopoiesis in mice induced by infection with murine cytomegalovirusHal E Broxmeyer, Alexander Dent, Scott Cooper, et al.Proceedings of the National Academy of Sciences of the United States of America|February 11, 2003
Defective presentation of the CD1d1-restricted natural Va14Ja18 NKT lymphocyte antigen caused by beta-D-glucosylceramide synthase deficiencyAleksandar K Stanic, A Dharshan De Silva, Jang-June Park, et al.Cancer Research|June 15, 2017
Characterization of MK-4166, a Clinical Agonistic Antibody That Targets Human GITR and Inhibits the Generation and Suppressive Effects of T Regulatory CellsSelvakumar Sukumar, Douglas C Wilson, Ying Yu, et al.Cell Reports|October 23, 2021
Targeting TREM2 on tumor-associated macrophages enhances immunotherapyMikhail Binnewies, Joshua L Pollack, Joshua Rudolph, et al.Pageof 3